ASCO 2016: A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high risk prostate cancer – results of SPCG12.

Goran Ahlgren, PhD.  discussed the initial results from the phase III prospective randomized trial sponsored by the Scandinavian Prostate Cancer Group, SPCG12. The purpose of this study was to use adjuvant chemotherapy to prolong the survival of men with high risk prostate cancer after radical prostatectomy.  The authors hypothesized that, similar to other solid tumors, adjuvant chemotherapy may prolong survival in the adjuvant setting as it does in the metastatic setting.

Read more ...

ASCO 2016: Quality of life (QOL) analysis from CHAARTED: Chemohormonal androgen ablation randomized trial in prostate cancer (E3805).

Linda Patrick-Miller, Ph.D, presented the quality of life analysis from the CHAARTED trial (Chemohormonal androgen ablation randomized trial in prostate cancer (E3805)) including men with metastatic hormone sensitive prostate cancer. A secondary endpoint of the study was to determine whether an increase in disease control with androgen deprivation therapy (ADT) plus docetaxel was associated with a change in quality of life. The study included patient reported outcomes on overall quality of life, disease related symptoms, and treatment related symptoms.

Read more ...
Page 4 of 4